Piper Jaffray analyst JP McKim raised his price target for DexCom to $116 citing two new data points and his consumer continuous glucose monitoring survey. The first data point, that Centers for Medicare & Medicaid Services will now allow Medicare patients to use their smart phone with CGM including the share function is a slight positive for DexCom, McKim tells investors in a research note. The second data point, which is the analyst was not able to confirm, is UnitedHealth (UNH) maybe moving to a bundled payment for CGM. And thirdly, McKim says his May consumer survey confirms a continued shift to CGM with more Type 2s is coming into the market. He believes DexCom remains the best way to play this trend and that the G6 launch will be a "meaningful driver of growth." The analyst keeps an Overweight rating on the shares

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here

Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here